Teva Pharmaceutical Industries has moved ecopipam substantially closer to the U.S. market after the United States Food and Drug Administration accepted its New Drug Application and granted Priority Review for treatment of pediatric Tourette syndrome. The agency is targeting a decision late in the first quarter of 2027, setting up a near-term regulatory test for a once-daily oral therapy designed to selectively block dopamine D1 receptors rather than the D2 receptors targeted by currently approved Tourette medicines.
The application is supported by positive Phase 2b and Phase 3 evidence, including a randomized withdrawal study in which pediatric patients who had already responded to ecopipam experienced a 53% lower risk of relapse when they continued treatment instead of transitioning to placebo. The result was statistically significant, with a hazard ratio of 0.47 and a p-value of 0.008, while ecopipam avoided several metabolic and movement-related safety problems associated with some existing dopamine-modulating treatments.
Priority Review moves ecopipam toward a late first-quarter 2027 FDA decision
The FDA’s acceptance confirms that Teva’s application is sufficiently complete to undergo substantive review, while Priority Review shortens the agency’s target review period for drugs considered capable of providing meaningful improvements in serious conditions. Ecopipam had already received FDA Fast Track and Orphan Drug designations for pediatric Tourette syndrome, giving the program several regulatory mechanisms intended to facilitate development and review.
Teva is seeking an indication specifically covering pediatric patients, even though the Phase 3 study also enrolled a small adult population. The D1AMOND Phase 3 trial enrolled 216 children, adolescents and adults into an initial open-label treatment period, with 104 responders eventually entering the randomized withdrawal phase. Ninety of those randomized participants were pediatric patients and 14 were adults.
Participants initially received ecopipam for 12 weeks, titrated toward a target dose of 1.8 milligrams per kilogram per day. Patients who achieved at least a 25% improvement on the Yale Global Tic Severity Scale Total Tic Score at weeks eight and 12 were considered responders and could enter the subsequent double-blind period, where they either continued ecopipam or were tapered to placebo for another 12 weeks.
The primary endpoint measured time to relapse, defined as losing at least half of the improvement obtained during open-label ecopipam therapy. Pediatric responders who remained on ecopipam showed a significantly lower relapse risk than those moved to placebo, producing the hazard ratio of 0.47. The adult subgroup showed a directionally similar hazard ratio of 0.51, although the analysis involved only 14 adults and was not statistically significant.
That trial structure creates an important limitation when interpreting the findings. Because only patients who had already demonstrated a clinically meaningful response to ecopipam entered the randomized withdrawal comparison, the Phase 3 result primarily establishes maintenance of benefit among responders rather than estimating how many untreated pediatric Tourette patients would respond if the medicine were introduced broadly. The study authors specifically identified this responder-enrichment design as a limitation on generalizability.
Phase 2b evidence showed tic reduction before Phase 3 tested whether that improvement could last
The earlier D1AMOND Phase 2b study provides complementary evidence because it evaluated symptom reduction directly rather than only maintenance among established responders. The randomized, double-blind and placebo-controlled study enrolled 153 pediatric participants across 68 clinical sites in North America and Europe.
At week 12, patients receiving ecopipam achieved a statistically significant and clinically meaningful improvement in Yale Global Tic Severity Scale Total Tic Score relative to placebo, with a p-value of 0.01. A subsequent open-label extension enrolled 121 children from that study and followed participants for as long as 12 months to examine longer-term tolerability and persistence of treatment effects.
Together, the studies answer different parts of the efficacy question. Phase 2b demonstrated that ecopipam could reduce tic severity compared with placebo during active treatment, while Phase 3 tested whether patients who achieved that improvement were more likely to maintain it if they stayed on therapy. The Phase 3 publication in JAMA Neurology concluded that clinically meaningful tic suppression could be maintained for as long as 24 weeks in the study setting.
Long-term evidence will remain important if ecopipam becomes a chronic treatment. Tourette symptoms can fluctuate naturally, and the pivotal study followed randomized patients for only 12 weeks after the initial 12-week open-label period. The investigators identified the limited 24-week safety assessment as another study limitation.
D1 receptor blockade could differentiate ecopipam from established Tourette medicines
Ecopipam’s mechanism is central to its potential therapeutic differentiation. The investigational drug selectively blocks dopamine D1 receptor signaling, based partly on the hypothesis that D1 receptor hypersensitivity contributes to repetitive and compulsive behaviors associated with Tourette syndrome. Current FDA-approved Tourette medications primarily modulate dopamine through D2 receptors.
Existing treatment can include alpha-2 adrenergic agonists such as clonidine or guanfacine, topiramate and antipsychotic medicines including risperidone, aripiprazole, pimozide and haloperidol depending on clinical circumstances. The JAMA Neurology investigators noted that antipsychotics can control tics but may be limited by weight gain, metabolic changes and drug-induced movement disorders.
Those safety considerations make ecopipam’s Phase 3 profile noteworthy. Across the clinical program, Teva reported no clinically meaningful effects on body weight or body mass index z-score, metabolic laboratory parameters or electrocardiogram measurements, while investigators found no signal for drug-induced movement disorders.
The most frequently reported adverse events during ecopipam exposure in the Phase 3 study included somnolence, anxiety, headache, insomnia, tics and fatigue. Investigators also reported suicidal ideation adverse events in five participants during the open-label ecopipam period, representing 2.3% of those participants, while one such event occurred among placebo recipients during randomized withdrawal. The study reported no negative impact on standardized measures for attention-deficit/hyperactivity disorder, anxiety, depression or obsessive-compulsive disorder.
A differentiated safety profile could become commercially important if confirmed through broader use, because treatment persistence remains a challenge in pediatric Tourette syndrome. Teva estimates that approximately 100,000 U.S. children and adolescents are affected, about half receive prescription medication and only 20% to 30% remain on therapy after one year.
FDA review quickly follows Teva’s $700m acquisition of ecopipam developer Emalex Biosciences
Teva only acquired control of ecopipam this summer. The company completed its acquisition of Emalex Biosciences on June 10, paying approximately $700 million upfront, with former Emalex shareholders eligible for as much as another $200 million in commercial milestone payments plus royalties on global ecopipam sales. Teva submitted the NDA eight days later on June 18.
The rapid progression from acquisition to accepted Priority Review illustrates why Teva considered ecopipam a late-stage addition rather than an early research bet. The company has been expanding its innovative neuroscience portfolio as part of its Pivot to Growth strategy, and regulatory approval would give it an opportunity to commercialize an asset with a mechanism distinct from currently approved pediatric Tourette therapies.
Teva Pharmaceutical Industries shares were trading around $37.38 on August 19, up approximately 2.2% from the previous close, with the company valued near $43.5 billion. The movement cannot be attributed solely to ecopipam, particularly given Teva’s size and diversified pharmaceutical business, but sentiment on the session was positive as the Priority Review milestone reduced one layer of regulatory uncertainty around the recently acquired asset.
The more important milestone now falls in late first-quarter 2027. Ecopipam has demonstrated both initial tic reduction and maintenance of benefit among pediatric responders, while its D1-selective mechanism could potentially avoid some limitations associated with existing dopamine D2-targeting medicines. The FDA review will determine whether that evidence is sufficient to translate a promising and differentiated clinical profile into the first newly indicated pediatric Tourette treatment in more than a decade.
